Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06560242 · ClinicalTrials.gov registry record · NA
Tracking Early Emergence of Sound Perception Impairments in FXS With Multimodal fNIRS/EEG- Infant
A NA study of Fragile X Syndrome, sponsored by Children's Hospital Medical Center, Cincinnati.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06560242: Recruiting NA study of Fragile X Syndrome, sponsored by Children's Hospital Medical Center, Cincinnati.
NCT06560242 is a NA study of Fragile X Syndrome that is actively recruiting participants, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 30 participants, below the 100-participant average among 16 other Fragile X Syndrome trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06560242, a NA study of Fragile X Syndrome, is actively recruiting participants, sponsored by Children's Hospital Medical Center, Cincinnati.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Individuals with Fragile X Syndrome show differences in how they understand and learn language from infancy. They frequently have lifelong delays in speech and language as well. In addition, they experience other auditory symptoms, including being very sensitive to certain sounds as well as being more sensitive than others to loud sounds. The underlying brain activity for sound perception and speech learning in Fragile X is not well understood, especially in the infant and toddler years. This study uses behavioral assessment of speech and language abilities, neuroimaging, and hearing tests to understand how speech and hearing are different in children with Fragile X Syndrome.
Primary Outcome
change in Mullen Scales scores (age-corrected) from baseline on all subscales, including Expressive Language, Receptive Language, FIne Motor, Gross Motor, and Visual Reception. T-Scores from the Mullen Scales of Early Learning (MSEL) have a mean of 50 and a standard deviation of 10. Range=20-80. Higher scores indicate more advanced developmental skills.
Conditions Studied
Interventions
- OTHER Speech discrimination
Study Locations (1)
Ohio
- Cincinnati Children's Hospital - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-10-31 |
| Est. Completion | 2026-10-31 |
| Phase | NA |
What NCT06560242 shows while recruiting
NCT06560242 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 100-participant average among 16 other Fragile X Syndrome trials with a reported enrollment target (70% lower).
The record links to 1 condition, with Fragile X Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Speech discrimination is the first listed.
NCT06560242 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT06560242 about?
NCT06560242 is a clinical study titled "Tracking Early Emergence of Sound Perception Impairments in FXS With Multimodal fNIRS/EEG- Infant". Individuals with Fragile X Syndrome show differences in how they understand and learn language from infancy. They frequently have lifelong delays in speech and language as well. In addition, they experience other auditory symptoms, including being very sensitive to certain sounds as well as being mo...
What is the current status of trial NCT06560242?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2022-10-31. Estimated completion is 2026-10-31.
What conditions does trial NCT06560242 study?
This clinical trial studies the following conditions: Fragile X Syndrome.
What interventions are being tested in trial NCT06560242?
The interventions under investigation include: Speech discrimination (OTHER).
Who is sponsoring clinical trial NCT06560242?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06560242 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fragile X Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06560242's enrollment target sits among peer trials
30 12th of 16 higher than 5 of 16 other Fragile X Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Fragile X Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Physical Activity and Community EmPOWERment Project
RECRUITING · NA
-
Web Intervention for Parents of Youth With Genetic Syndromes (WINGS)
RECRUITING · NA
-
Tracking Early Emergence of Sound Perception Impairments in FXS With Multimodal fNIRS/EEG-Preschool Age
RECRUITING · NA
-
Speech-in-noise Perception in Autism and Fragile X
RECRUITING · NA
-
Alpha Auditory Entrainment for Cognitive Enhancement and Sensory Hypersensitivity in Youth With Developmental Disorders
RECRUITING · NA
-
Trial of Minocycline to Treat Children With Fragile X Syndrome
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI